Last checked at 7 Oct 2019 07:00
(AIM:SAR)
7 October 2019
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
NOTICE OF FULL YEAR 2019 RESULTS
Sareum Holdings plc (AIM: SAR), the specialised small molecule drug development business, will announce its results for the full year ended 30 June 2019 on Tuesday 15 October.
A conference call will take place on the same day at 10:00am. Stephen Parker, Chairman, Tim Mitchell, Chief Executive Officer and John Reader, Chief Scientific Officer, will present the financial and operational results followed by a Q&A session.
Dial-in details for the conference call are:
·; UK Toll Free: 0808 109 0700
·; Standard International Access: +44 (0)20 3003 2666
The call password is Sareum.
The results presentation will be available in the Document Centre in the Investors section of the Sareum website (www.sareum.com/investors) from 7:00am the same day.
For further information, please contact:
Sareum Holdings plc |
|
Tim Mitchell | 01223 497 700 |
Strand Hanson Limited (Nominated Adviser) | |
James Dance / Richard Tulloch | 020 7409 3494 |
Hybridan LLP (Nominated Broker) |
|
Claire Noyce / John Beresford-Peirse | 020 3764 2341 |
Citigate Dewe Rogerson (Media enquiries) |
|
Shabnam Bashir / Mark Swallow / David Dible | 020 7638 9571 |
Notes for editors:
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting first human clinical trials in each indication in 2020.
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a $328.5m plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk
- Ends -